CD3E and neoplasm: The inhibition of CD3ε enhanced γδ TCR signaling through stabilization of the active CD3 conformation, as well as activation and tumor-killing efficacy of these γδ T cells – by an unknown mechanism, although independent of Nck recruitment to the γδ TCR – leading to an increased γδ T cell–mediated release of cytotoxic granules and cancer cell lysis, thus denoting successful in vitro and in vivo preclinical trials against B-cell lymphoma and pancreatic ductal adenocarcinoma [199, 200].